Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech and life sciences company whose news flow centers on clinical trial progress, regulatory milestones, strategic collaborations and capital markets activity. The company describes itself as a precision guided biotech/life sciences organization focused on advancing SkinJect™, an investigational microneedle therapy for basal cell carcinoma (BCC) of the skin, and Teverelix, a long-acting GnRH antagonist for hormone-driven conditions.
News updates frequently cover the SkinJect™ program, including Phase 2 study SKNJCT-003 in the United States, regulatory and ethics approvals to expand into the United Kingdom, and SKNJCT-004 in the United Arab Emirates. Releases also highlight interactions with the U.S. Food and Drug Administration (FDA), such as Type C meeting feedback supporting a 505(b)(2) regulatory pathway and the filing of an FDA Commissioner’s National Priority Voucher (CNPV) application for SKNJCT-003.
Another major theme in MDCX news is the Teverelix pipeline, added through the acquisition of Antev Limited. Company communications describe prior Phase 1 and Phase 2a data, FDA guidance on Phase 3 design, and plans to use AI-enabled analytics—via an engagement with Reliant AI Inc.—to support upcoming Teverelix clinical studies. Additional coverage includes Phase 1 data in healthy female volunteers and acceptance of Teverelix research for presentation at a leading endocrinology conference.
Investors following MDCX news will also see announcements on collaborations, such as the Gorlin Syndrome Alliance partnership for compassionate access to SkinJect™ and a non-binding memorandum of understanding with Helix Nanotechnologies, Inc. around thermostable infectious disease vaccines. Capital markets updates, including warrant inducement agreements, standby equity purchase activity and debenture financings, are disclosed through press releases and Form 8-K filings.
This news page aggregates these developments so readers can review Medicus Pharma’s clinical, regulatory, partnering and financing announcements in one place.
Medicus Pharma (NASDAQ: MDCX) outlined its development priorities in a shareholder update covering three years of financing and portfolio expansion. Approximately $90 million raised through equity and debt supported clinical development, acquisitions and operations, while retaining resources for ongoing requirements.
The company plans to prioritize melanoma development for CD228V, an antibody-linked cancer drug. For SkinJect, it completed the Phase 2 SKNJCT-003 study, selected the 200-microgram dose and received FDA authorization to initiate the planned SKNJCT-005 registrational study in Gorlin syndrome. The August 2025 Antev acquisition added Teverelix; its royalty rate was subsequently reduced. A proposed integrated prostate cancer development protocol remains subject to FDA review.
Medicus intends to align costs with selected milestones and pursue partnerships, whose timing, terms and completion remain uncertain. The update also acknowledged stock-price volatility and pullback.
Medicus Pharma (MDCX) submitted a proposed Phase 2b/3 Teverelix protocol to the FDA for advanced prostate cancer patients at increased cardiovascular risk. The design begins with approximately 80 randomized patients, replacing a previously FDA-cleared, stand-alone 40-patient dose-optimization study. If predefined continuation criteria are met, approximately 528 more patients would join, bringing planned enrollment to approximately 608. Eligible first-stage patients would contribute to the final analyses.
The company believes FDA agreement could reduce its previously discussed clinical program from approximately 1,500 patients to approximately 600. The proposed study would assess testosterone suppression and coronary non-calcified plaque at 12 months, with longer-term cardiovascular event follow-up. After FDA feedback, Medicus intends to seek a partner to fund and execute further development rather than finance the proposed study itself.
Medicus Pharma (MDCX) will focus all future internally sponsored clinical development of SkinJect® on Gorlin syndrome patients with multiple basal cell carcinoma lesions and conclude further development in sporadic/nodular basal cell carcinoma.
The decision follows a comprehensive assessment that included an independent commercial study, clinical input from the SKNJCT-003 Phase 2 investigator, the final Phase 2 Clinical Study Report and feedback from the FDA’s Office of Orphan Products Development on Orphan Drug and Rare Pediatric Disease designation requests. The FDA has authorized the NDA-enabling, registrational Phase 2b SKNJCT-005 study in Gorlin syndrome with a 200-µg doxorubicin-loaded microneedle patch as the proposed pivotal dose. A 2026 commercial assessment modeled rare-disease net pricing of about $25,800 per treatment, with non-risk-adjusted U.S. market and revenue scenarios dependent on successful development and approval.
Medicus Pharma (MDCX) has posted an abridged final Clinical Study Report (CSR) for its completed Phase 2 SKNJCT-003 trial of SkinJect® in nodular basal cell carcinoma on ClinicalTrials.gov, identifying the 200 µg D-MNA patch as the proposed pivotal dose.
The randomized, double-blind, multicenter study enrolled 90 patients at ten U.S. sites, with all patients completing treatment and follow-up, providing a full dataset for efficacy and safety analyses. The CSR underpins a refined development plan that adopts a composite complete-response endpoint (clinical plus histological clearance), later primary efficacy assessment timing, and a non-penetrating sham comparator for future registrational work. Medicus is prioritizing the FDA-authorized NDA‑enabling Phase 2b SKNJCT‑005 study in Gorlin syndrome patients with multiple BCC lesions and seeks partners for nodular BCC. The FDA has issued a “Study May Proceed” letter for SKNJCT‑005, which is expected to enroll up to approximately 50 patients.
Medicus Pharma (MDCX) announced a strategic shift to become a precision oncology-led biotechnology company centered on its CD228V antibody-drug conjugate program.
CD228V, a second-generation ADC targeting melanotransferrin/CD228 in solid tumors, is now the Company’s principal priority, with initial development focused on establishing clinical proof-of-concept in melanoma, particularly relapsed or refractory disease. The program is backed by an active U.S. IND and a first-in-human Phase 1 trial (NCT06799533). Medicus is also refocusing SkinJect® on Gorlin syndrome, with FDA authorization to initiate SKNJCT-005, an NDA-enabling registrational Phase 2b study in patients with multiple BCCs. For Teverelix®, the Company plans to prioritize an approximately 126-patient Phase 2 acute urinary retention study and the PRECISION-E2 Phase 2a endometriosis trial while seeking partnerships in advanced prostate cancer.
Medicus Pharma (NASDAQ:MDCX) reported Q2 2026 results and regulatory progress across its SkinJect and Teverelix programs. According to Medicus Pharma, cash, cash equivalents and restricted cash totaled $25.2 million on June 30, 2026, with cash and cash equivalents of $15.2 million, up from $9.7 million a year earlier. Year to date, the company raised approximately $40 million through equity and debt, including use of its ATM program and a secured facility, though substantial doubt remains about its ability to continue as a going concern without further financing.
Q2 operating expenses (loss from operations) were $11.5 million versus $6.0 million in Q2 2025, and net loss was $11.7 million versus $6.2 million, with net loss per share of $0.21 versus $0.43. Medicus reported positive Phase 2 SkinJect data (64% clinical and 55% histological clearance at the 200 μg dose) and FDA “Study May Proceed” authorization for the registrational SKNJCT-005 trial in Gorlin Syndrome. It also received IRB authorization and favorable FDA feedback for an optimized Phase 2 Teverelix study in acute urinary retention and UAE DOH authorization for the PRECISION-E2 Phase 2 study in endometriosis.
Medicus Pharma (Nasdaq: MDCX) appointed Dr. Faisal Mehmud, MD, MRCP as Chief Executive Officer of its UK subsidiary Antev Limited, effective August 30, 2026, while he continues as Medicus Chief Medical Officer and Co-Chairman of Antev.
According to Medicus, consolidating these roles is intended to provide unified scientific, clinical, regulatory and operational leadership as the company advances Teverelix®, a next-generation GnRH antagonist in late-stage clinical development for advanced prostate cancer, acute urinary retention and women’s health indications such as endometriosis. Dr. Mehmud succeeds interim CEO Amit Kohli, who agreed at Antev’s August 29, 2025 acquisition to remain for one year to support transition. Dr. Mehmud brings over 20 years of global biopharmaceutical leadership across clinical development, medical affairs, regulatory strategy and pharmacovigilance at companies including Pfizer, GSK, Bristol Myers Squibb, Novartis and Sanofi.
Medicus Pharma (NASDAQ: MDCX) received Investigational New Drug authorization from the UAE Department of Health – Abu Dhabi for its randomized, placebo-controlled Phase 2a PRECISION-E2 clinical study of Teverelix® in approximately 84 women with moderate-to-severe symptomatic endometriosis. The DOH authorization follows a comprehensive review of chemistry, manufacturing and controls, non-clinical, clinical and safety data and allows the study to proceed, subject to site-specific IRB and ethics approvals.
PRECISION-E2 will test multiple Teverelix® doses and routes versus placebo, focusing on maintaining serum estradiol in the Barbieri therapeutic window for at least 14 consecutive days, while integrating pharmacodynamic, pharmacokinetic, biomarker, clinical and whole-genome data to explore candidate treatment-response biomarkers for future precision medicine strategies in women’s health.
Medicus Pharma (NASDAQ: MDCX) received an FDA “Study May Proceed” letter for its NDA-enabling, registrational Phase 2b study SKNJCT-005, evaluating SkinJect® (D‑MNA) 200 mcg in Gorlin Syndrome patients with multiple basal cell carcinomas. The open-label, multicenter trial is expected to enroll up to 50 patients.
According to Medicus, FDA feedback led to protocol enhancements including mandatory baseline biopsy confirmation of nodular BCC, a composite primary endpoint requiring both clinical and histological clearance, in-person investigator assessments, aligned responder definitions, and extended follow-up from 24 weeks to at least two years to assess durability. Prior SKNJCT-003 data in 90 patients showed 64% clinical and 55% histological clearance at Day 57 after three 200‑mcg treatments.
The FDA also issued non–clinical-hold recommendations on pharmacokinetics, microneedle evaluation, genetic confirmation of Gorlin Syndrome, independent safety monitoring, statistical methods, and future randomized, blinded, comparator-controlled designs. Medicus plans to amend the SKNJCT-005 protocol and provide further updates as study initiation and enrollment planning advance.
Medicus Pharma (NASDAQ: MDCX) received written feedback from the FDA and central IRB approval, with modifications, for its optimized Phase 2 ANT-2111-02 study of Teverelix in men after a first episode of acute urinary retention secondary to benign prostatic hyperplasia.
The redesigned randomized, double-blind, placebo-controlled multicenter trial will enroll about 126 patients in the US and Europe versus roughly 390 in the prior plan, and will test intramuscular and subcutaneous Teverelix regimens against placebo. According to Medicus Pharma, FDA comments dated July 8, 2026 are operational, not affecting scientific rationale, population, treatment arms, primary endpoint or interim analysis. Central IRB Advarra approved the protocol on June 18, 2026, with approval through June 18, 2027, enabling study start-up and site activation activities.